Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T9700 |
EZH2-IN-2
|
Histone Methyltransferase | Chromatin/Epigenetic |
EZH2-IN-2 是一种 EZH2 抑制剂,IC50 值为 64 nM。EZH2-IN-2 可用于研究与 EZH2 活性相关的癌症或癌前病变。 | |||
T40323 |
EZH2-IN-6
EZH2-IN-6 |
||
EZH2-IN-6 is an EZH2 inhibitor with enhanced antitumor activity. | |||
T38827 |
EZH2-IN-5
EZH2-IN-5 |
||
EZH2-IN-5 is a highly effective inhibitor of EZH2, displaying remarkable potency against both wild-type and mutant Tyr641 EZH2, with IC50 values of 1.52 nM and 4.07 nM, respectively. | |||
T39497 |
EZH2-IN-4
EZH2-IN-4 |
||
EZH2-IN-4 is a highly potent EZH2 inhibitor that can be taken orally. It exhibits inhibitory effects against wild type (WT) 5-membered (5-mer) EZH2 and mutant 5-mer EZH2, with IC 50 values of 0.923 nM and 2.65 nM, respectively. Moreover, EZH2-IN-4 has demonstrated significant anti-cancer activity. | |||
T64043 |
EZH2-IN-13
|
Histone Methyltransferase | Chromatin/Epigenetic |
EZH2-IN-13 是一种有效的 EZH2 抑制剂,具有潜在的抗癌活性。EZH2-IN-13 可用于研究与 EZH2 活性相关的疾病。 | |||
T40310 |
PARP/EZH2-IN-1
PARP/EZH2-IN-1 |
||
PARP/EZH2-IN-1 is a novel compound that functions as a dual inhibitor for both PARP (IC50 6.87 nM) and EZH2 (IC50 36.51 nM), showing promising potential for the treatment of triple-negative breast cancer with wild-type BRCA. | |||
T25400 |
EZH2-IN-3
EZH2 inhibitor 3,EZH2-inhibitor-3 |
||
EZH2-IN-3 is an inhibitor of EZH2 and EZH1 with selective impact on diffuse large B cell lymphoma cell growth. | |||
T74602 |
PROTAC EZH2 Degrader-1
|
||
PROTACEZH2 Degrader-1 (Compound 150d)是高效的PROTACEZH2降解剂,能够抑制EZH2甲基转移酶的活性,其IC50值为2.7 nM。由于EZH2在许多肿瘤的发生及进展中具有关键作用,这种化合物的研发具有重要意义。 | |||
T67883 |
EZH2-IN-15
SHR2554 |
Histone Methyltransferase | Chromatin/Epigenetic |
EZH2-IN-15 是zeste 2组蛋白修饰增强子(EZH2)的特异性抑制剂。EZH2在许多人类癌症中异常过表达,通过调节Treg 活性来控制适应性反应。肿瘤内EZH2的表达也被证明可以控制先天免疫 | |||
T74675 |
MS8815
|
||
MS8815 是 zeste 同源物2(EZH2)PROTAC 降解剂,具有选择性。MS8815 对 EZH2有抑制活性,IC50值为 8.6 nM。MS8815 可用于三阴性乳腺癌 (TNBC) 研究。 |